BCL2 and B-cell chronic lymphocytic leukemia: This compound binds Bcl-2 protein in vitro with subnanomolar affinities and inhibits tumour growth of chronic lymphocytic leukaemia (CLL) when combined with rituximab in phase II of clinical trial.